Horizontal Tabs

Treatment Modalities 
Cell Therapy
Therapeutic vaccines
Facilities/Translational Research 

Phase I capability

  • First-in-man studies
  • Site for multi-centre phase I studies
  • Co-ordination and management of phase I studies through the Liverpool Cancer Trials Unit
  • Phase I population: Adult solid tumours and haematological malignancies
  • Phase I mechanisms:  Immunotherapy, cell therapy

Centre specific translational research interest

  • Pancreatic cancer and haemato-oncology
  • Biomarker discovery and validation
  • Clinical pharmacology

Technology/equipment within the centre


  • Good Clinical Practice Laboratory
  • Freezers and fridges (9 minus 80°C freezers, 6 minus 150°C freezers, 3 minus 20°C freezers, 1 minus 30°C freezer and 2 large 4°C degree fridges).  All temperatures are monitored with independent probes attached to the Pharmagraph Environmental Monitoring System. The total storage space exceeds 600,000 1.5 ml tubes
  • Customised Matrix Laboratory Information Management System with individual trial workflows – hierarchical and fully auditable
  • Immunomonitoring: Plate reader and washer, Luminex, reader/imager, beta counter, Tomtec cell harvester
  • Cytometry: FACSCanto/FACSFortesa, centrifuges, nucleocounter
  • Molecular biology and histology: PCR machines (including LightCycler and Bio-Rad), ProKyma bead separation, Maxwell rapid sample concentrator robot, OneTouch, Ion torrent next generation sequencer, TMA arrayer, heating block, Chemidoc digital imager

Assays – Clinical Trial Support

  • Immunohistochemistry and in-situ hybridisation (RNAScope)
  • Proliferation assays (T-cell response to immune therapy and vaccines)
  • Cytokine quantification using Luminex (various panels but principally 27plex from Bio-Rad)
  • Minimal Residual Disease (MRD) by FACS analysis
  • P53 codon 31 SNP analysis (in CLL) by FACS
  • Real Time PCR analysis
  • Limiting dilution NGS analysis of Tp53 (for CTC detection and analysis)

Other facilities

  • CRUK Liverpool Cancer Trials Unit
  • Seven further chemotherapy clinics covering Cheshire and Merseyside

Other offsite facilities and equipment

  • Royal Liverpool Clinical Research Unit (MHRA Standard and Supplementary Phase I Accredited Site)

Sample Collection

  • Tissue banking activity: Pancreas Cancer Biobank, UK Chronic Lymphocytic Leukaemia (CLL) Trials Biobank, Clatterbridge Cancer Centre (CCC) Biobank, Peripheral T-Cell Lymphoma Biobank, Mantle Cell Lymphoma Biobank
  • Centre contacts responsible for sample collection: Pancreas Cancer Biobank (Dr Bill Greenhalf), UK CLL Trials Biobank (Dr Mel Oates), CCC Biobank (Dr Maria Maguire)